Drug Approval | December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Subscribe To Our Newsletter & Stay Updated
